TABLE OF CONTENTS
1 INTRODUCTION 30
1.1 OBJECTIVES OF THE STUDY 30
1.2 MARKET DEFINITION 30
1.3 OVERVIEW OF THE ASIA-PACIFIC STOOL DIAGNOSTIC MARKET 30
1.4 LIMITATIONS 32
1.5 MARKETS COVERED 32
2 MARKET SEGMENTATION 35
2.1 MARKETS COVERED 35
2.2 GEOGRAPHICAL SCOPE 36
2.3 YEARS CONSIDERED FOR THE STUDY 36
2.4 CURRENCY AND PRICING 36
2.5 DBMR TRIPOD DATA VALIDATION MODEL 37
2.6 MULTIVARIATE MODELLING 40
2.7 TEST TYPE LIFELINE CURVE 40
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 41
2.9 DBMR MARKET POSITION GRID 42
2.10 MARKET APPLICATION COVERAGE GRID 44
2.11 VENDOR SHARE ANALYSIS 45
2.12 SECONDARY SOURCES 46
2.13 ASSUMPTIONS 46
3 EXECUTIVE SUMMARY 47
4 PREMIUM INSIGHTS 50
4.1 PESTEL ANALYSIS 51
4.2 PORTERS FIVE FORCES 52
5 INDUSTRY INSIGHTS 53
6 REGULATIONS 54
7 MARKET OVERVIEW 57
7.1 DRIVERS 59
7.1.1 INCREASING PREVALENCE OF GASTROINTESTINAL DISEASE 59
7.1.2 INCREASING PREVALENCE OF ESOPHAGEAL, COLORECTAL, AND GASTRIC CANCERS 59
7.1.3 RISING DEMAND FOR EARLY DISEASE DIAGNOSIS 60
7.2 RESTRAINTS 62
7.2.1 STRICT GOVERNMENT REGULATIONS 62
7.2.2 HIGH COST ASSOCIATED WITH STOOL DIAGNOSIS 63
7.3 OPPORTUNITIES 64
7.3.1 ADVANCEMENTS IN SAMPLE COLLECTION AND HANDLING FOR STOOL DIAGNOSTICS 64
7.3.2 RISING DEMAND FOR NON-INVASIVE OR MINIMAL INVASIVE STOOL DIAGNOSTICS 64
7.4 CHALLENGES 65
7.4.1 LACK OF SKILLED & CERTIFIED PROFESSIONALS 65
7.4.2 LACK OF STANDARDIZATION IN STOOL DIAGNOSTIC PROCEDURE 66
8 ASIA-PACIFIC STOOL DIAGNOSTIC MARKET, BY TEST TYPE 67
8.1 OVERVIEW 68
8.2 PATHOGEN TEST 71
8.2.1 H. PYLORI TEST 71
8.2.1.1 H. PYLORI ANTIGEN TEST 72
8.2.1.2 UREA BREATH TEST 72
8.2.2 C. DEFFCILE TEST 72
8.2.3 OVA & PARASITE TEST 72
8.2.4 ROTAVIRUS TEST 72
8.2.5 ADENOVIRUS TEST 72
8.2.6 SALMONELLA CULTURE TEST 72
8.2.7 CAMPYLOBACTER TEST 73
8.2.8 EHEC TEST 73
8.2.9 OTHERS 73
8.3 FECAL OCCULT BLOOD TEST 73
8.3.1 LATERAL FLOW IMMUNO-FOB TEST 74
8.3.2 IMMUNO-FOB AGGLUTINATION TEST 74
8.3.3 GUAIC FOB STOOL TEST 74
8.3.4 OTHERS 74
8.4 FECAL BIOMARKERS TEST 74
8.4.1 INFLAMMATORY BIOMARKERS TEST 75
8.4.1.1 FECAL CALPROTECTIN 75
8.4.1.2 FECAL LACTOFERRIN 75
8.4.1.3 OTHERS 75
8.4.2 CANCER BIOMARKERS TEST 76
8.4.2.1 COLOGUARD 76
8.4.2.2 M2 PK STOOL TEST 76
8.4.2.3 OTHERS 76
8.4.3 OTHERS 76
8.5 MICROSCOPY TEST 77
8.6 STOOL ANTIGEN TEST 77
8.7 FECAL ELASTASE TEST 77
8.8 OTHER TESTS 78
9 ASIA-PACIFIC STOOL DIAGNOSTIC MARKET, BY PRODUCT TYPE 79
9.1 OVERVIEW 80
9.2 REAGENTS 83
9.2.1 FECAL FLOAT SOLUTIONS 83
9.2.2 BUFFER SOLUTIONS 83
9.2.3 ABSOLUTE METHANOL 83
9.2.4 ACID ALCOHOL 84
9.2.5 OTHERS 84
9.3 INSTRUMENTS 84
9.3.1 FECALYZERS 85
9.3.2 DIGITAL SCALES 85
9.3.3 MICROSCOPES 85
9.3.4 MICROSCOPE SLIDES 85
9.3.5 MICROSCOPE COVER SLIPS 85
9.3.6 OTHERS 85
10 ASIA-PACIFIC STOOL DIAGNOSTIC MARKET, BY MODE 86
10.1 OVERVIEW 87
10.2 LABORATORY BASED TESTING 90
10.3 POINT OF CARE TESTING 90
11 ASIA-PACIFIC STOOL DIAGNOSTIC MARKET, BY APPLICATION 91
11.1 OVERVIEW 92
11.2 DIARRHEA 95
11.3 IRRITABLE BOWEL SYNDROME 95
11.4 HEMORRHOIDS 95
11.5 ULCERATIVE COLITIS 96
11.6 CANCER 96
11.6.1 COLORECTAL 97
11.6.2 COLON 97
11.6.3 OTHER 97
11.7 CROHNS DISEASE 97
11.8 OTHERS 98
12 ASIA-PACIFIC STOOL DIAGNOSTIC MARKET, BY END USER 99
12.1 OVERVIEW 100
12.2 HOSPITALS 103
12.3 DIAGNOSTIC CENTERS 103
12.4 LABORATORIES 103
12.5 SPECIALTY CLINICS 104
12.6 ACADEMIC INSTITUTES AND RESEARCH CENTERS 104
12.7 OTHERS 105
13 ASIA-PACIFIC STOOL DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL 106
13.1 OVERVIEW 107
13.2 DIRECT TENDERS 110
13.3 RETAIL SALES 110
13.4 ONLINE SALES 110
13.5 OTHERS 111
14 ASIA-PACIFIC STOOL DIAGNOSTIC MARKET BY REGION 112
14.1 ASIA-PACIFIC 112
14.1.1 CHINA 118
14.1.2 JAPAN 123
14.1.3 INDIA 128
14.1.4 SOUTH KOREA 133
14.1.5 AUSTRALIA 138
14.1.6 MALAYSIA 143
14.1.7 INDONESIA 148
14.1.8 PHILIPPINES 154
14.1.9 THAILAND 159
14.1.10 NEW ZEALAND 164
14.1.11 TAIWAN 169
14.1.12 VIETNAM 174
14.1.13 HONG KONG 179
14.1.14 SINGAPORE 184
14.1.15 PAKISTAN 189
14.1.16 BANGLADESH 194
14.1.17 SRI LANKA 199
14.1.18 CAMBODIA 204
14.1.19 NEPAL 209
14.1.20 MONGOLIA 214
14.1.21 LAOS 219
14.1.22 MALDIVES 224
14.1.23 BRUNEI 229
14.1.24 REST OF ASIA-PACIFIC 234
15 ASIA-PACIFIC STOOL DIAGNOSTIC MARKET: COMPANY LANDSCAPE 235
15.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 235
16 SWOT ANALYSIS 236
17 COMPANY PROFILE 237
17.1 EIKEN CHEMICAL CO., LTD. 237
17.1.1 COMPANY SNAPSHOT 237
17.1.2 REVENUE ANALYSIS 237
17.1.3 PRODUCT PORTFOLIO 238
17.1.4 RECENT DEVELOPMENT 238
17.2 QUIDEL CORPORATION 239
17.2.1 COMPANY SNAPSHOT 239
17.2.2 REVENUE ANALYSIS 239
17.2.3 PRODUCT PORTFOLIO 240
17.2.4 RECENT DEVELOPMENTS 240
17.3 BIOMERIEUX 241
17.3.1 COMPANY SNAPSHOT 241
17.3.2 REVENUE ANALYSIS 241
17.3.3 PRODUCT PORTFOLIO 242
17.3.4 RECENT DEVELOPMENTS 242
17.4 SD BIOSENSOR, INC. 243
17.4.1 COMPANY SNAPSHOT 243
17.4.2 REVENUE ANALYSIS 243
17.4.3 PRODUCT PORTFOLIO 244
17.4.4 RECENT DEVELOPMENTS 244
17.5 SEKISUI DIAGNOSTICS (A PART OF SEKISUI CHEMICAL CO. LTD.) 245
17.5.1 COMPANY SNAPSHOT 245
17.5.2 REVENUE ANALYSIS 245
17.5.3 PRODUCT PORTFOLIO 246
17.5.4 RECENT DEVELOPMENTS 246
17.6 ABBOTT 247
17.6.1 COMPANY SNAPSHOT 247
17.6.2 REVENUE ANALYSIS 247
17.6.3 PRODUCT PORTFOLIO 248
17.6.4 RECENT DEVELOPMENT 248
17.7 ADVACARE PHARMA 249
17.7.1 COMPANY SNAPSHOT 249
17.7.2 PRODUCT PORTFOLIO 249
17.7.3 RECENT DEVELOPMENTS 249
17.8 ALFA SCIENTIFIC DESIGNS, INC. 250
17.8.1 COMPANY SNAPSHOT 250
17.8.2 PRODUCT PORTFOLIO 250
17.8.3 RECENT DEVELOPMENTS 250
17.9 BECKMAN COULTER, INC. (SUBSIDIARY OF DANAHER) 251
17.9.1 COMPANY SNAPSHOT 251
17.9.2 REVENUE ANALYSIS 251
17.9.3 PRODUCT PORTFOLIO 252
17.9.4 RECENT DEVELOPMENTS 252
17.10 BEIJING HUAGEN ANBANG TECHNOLOGY CO., LTD. 253
17.10.1 COMPANY SNAPSHOT 253
17.10.2 PRODUCT PORTFOLIO 253
17.10.3 RECENT DEVELOPMENT 253
17.11 BIOVENDOR GROUP 254
17.11.1 COMPANY SNAPSHOT 254
17.11.2 PRODUCT PORTFOLIO 254
17.11.3 RECENT DEVELOPMENTS 254
17.12 CENOGENICS CORPORATION 255
17.12.1 COMPANY SNAPSHOT 255
17.12.2 PRODUCT PORTFOLIO 255
17.12.3 RECENT DEVELOPMENTS 255
17.13 DIASORIN S.P.A. 256
17.13.1 COMPANY SNAPSHOT 256
17.13.2 REVENUE ANALYSIS 256
17.13.3 PRODUCT PORTFOLIO 257
17.13.4 RECENT DEVELOPMENT 257
17.14 KIBION GMBH (A SUBSIDIARY OF OREXO AB) 258
17.14.1 COMPANY SNAPSHOT 258
17.14.2 REVENUE ANALYSIS 258
17.14.3 PRODUCT PORTFOLIO 259
17.14.4 RECENT DEVELOPMENTS 259
17.15 LIFESIGN LLC 260
17.15.1 COMPANY SNAPSHOT 260
17.15.2 PRODUCT PORTFOLIO 260
17.15.3 RECENT DEVELOPMENTS 260
17.16 MERIDIAN BIOSCIENCE INC. 261
17.16.1 COMPANY SNAPSHOT 261
17.16.2 REVENUE ANALYSIS 261
17.16.3 PRODUCT PORTFOLIO 262
17.16.4 RECENT DEVELOPMENT 262
17.17 MOLBIO DIAGNOSTICS PVT. LTD. 263
17.17.1 COMPANY SNAPSHOT 263
17.17.2 PRODUCT PORTFOLIO 263
17.17.3 RECENT DEVELOPMENT 263
17.18 PRENETICS LIMITED 264
17.18.1 COMPANY SNAPSHOT 264
17.18.2 REVENUE ANALYSIS 264
17.18.3 PRODUCT PORTFOLIO 265
17.18.4 RECENT DEVELOPMENT 265
17.19 RUNMEI 266
17.19.1 COMPANY SNAPSHOT 266
17.19.2 PRODUCT PORTFOLIO 266
17.19.3 RECENT DEVELOPMENTS 266
17.20 TRANSGEN BIOTECH CO., LTD. 267
17.20.1 COMPANY SNAPSHOT 267
17.20.2 PRODUCT PORTFOLIO 267
17.20.3 RECENT DEVELOPMENT 267
18 QUESTIONNAIRE 268
19 RELATED REPORTS 272

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.